Molecular Devices Partners with Roche to Develop Custom Ruthenium Nano-TRF Detection Platform

Nov 03, 2014

Sunnyvale, CA November 3, 2014 – The custom technologies arm of Molecular Devices, a leader in bioanalytical systems for drug discovery, life science research, and bioassay development, has partnered with the Discovery Technologies team at the Roche Innovation Center Basel of Pharma Research and Early Development (pRED) to develop a high-throughput detection system for drug discovery screens employing Roche’s proprietary Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF®) assays. The pRED screening teams in Basel and Shanghai are now installing the custom-developed Nano-TRF® cartridge in their existing Molecular Devices SpectraMax® Paradigm® multimode microplate readers and will receive on-demand delivery of new cartridges and continuing global technical support.

Nano-TRF® is a robust, Ruthenium-based time-resolved assay used in high-throughput screening for drug discovery. Ruthenium-based dyes combine the advantages of the Lanthanide (e.g. Eu, Tb) based time-resolved detection and nanosecond fluorophores: the high quantum efficiency Ruthenium-dyes have bright far-red signals with low background due to time resolved detection, do not require strong UV excitation but rather can be excited with visible light, are chemically robust, and have proven and stable detection in many biological matrices. However, the instrumentation for proper and scalable implementation of Ruthenium Nano-TRF® had not previously been developed.

“We make the instruments that only existed as ideal specs in a team meeting or a protocol draft,” says Shawn M M Laymon, VP of Molecular Devices Global Services & Custom Solutions. “We look forward to a continued relationship with Roche and to building new relationships with customers looking for a partner to help them create custom detection and analysis systems that meet their specific workflow needs.”

Molecular Devices’ SpectraMax Paradigm Multi-Mode Detection Platform employs a cartridge-based system that expands the capability of the plate reader beyond traditional assays to include applications such as western blotting and imaging cytometry. Users can choose from more than 20 existing cartridges or engage Molecular Devices Custom Technologies to create a cartridge that fits their needs.

More information about instruments and Molecular Devices Custom Technologies is available at www.moleculardevices.com.

Nano-TRF® is a registered trademark of Roche Diagnostics, GmbH. SpectraMax® and Paradigm® are registered trademarks of Molecular Devices, LLC.

Molecular Devices products are for Research Use Only and not for use in diagnostic procedures.

About the SpectraMax® Paradigm® Multi-Mode Detection System

The SpectraMax® Paradigm® Multi-Mode Detection System can perform absorbance, fluorescence, time-resolved fluorescence (including HTRF), fluorescence polarization, AlphaScreen®, AlphaLISA®, and luminescence measurements. Detection cartridge modularity allows users to configure the system to meet their current needs, while providing flexibility to address future applications. SoftMax® Pro Microplate Data Acquistion & Analysis Software, Molecular Devices industry leading all-in-one data acquisition and analysis software, comes standard with the Paradigm Platform. SpectraDrop™ Plate protocols that enable Micro Volume applications measurement are also included.